GCIFutura Medical: Trinity Delta Lighthouse
Haleon, commercial partner for Eroxon in the US market, has announced it intends to make Eroxon available in the US before the end of 2024. Haleon had previously only stated, during analyst Q&A as part of FY23 results in February, that US launch was expected “within the next 12 months” ie by February 2025. The importance of the clarification lies in the timing of the expected US launch milestone being triggered, which should propel Futura to profitability in FY24. Our current forecasts conservatively model a US launch in FY25.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.